California’s BridgeBio Pharma (Nasdaq: BBIO) and German life sciences company Bayer (BAYN: DE) have announced a collaboration.
The deal will see BridgeBio grant Bayer an exclusive license to commercialize acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe.
"This partnership leverages Bayer’s established European cardiovascular infrastructure"In exchange, BridgeBio will receive up to $310 million comprising of upfront and near-term milestone payments, as well as additional undisclosed sales milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze